DYAI NASDAQ
Dyadic International, Inc.
1W: +12.3%
1M: -10.9%
3M: -51.7%
YTD: -50.3%
1Y: -64.1%
3Y: -75.7%
5Y: -91.8%
$0.46
+0.03 (+6.10%)
Weekly Expected Move ±12.3%
$0
$0
$0
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
12 relationships12
As Filer
counterparties named
0
As Counterparty
mentioned by others
5
Rel. Types
2021-03-18
Earliest Filing
2026-03-06
Latest Filing
partner: 6
licensee: 2
supplier: 2
investor: 1
target: 1
Counterparties (Filed by DYAI)
12 relationshipsCompanies named in DYAI's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Craig-Hallum Capital Group LLC | — | partner | Sales agent for the at-the-market issuance of common stock | 2026-03-06 | View |
| Craig-Hallum Capital Group LLC | — | partner | Underwriter for the sale of 6,052,000 shares of common stock. | 2025-08-01 | View |
| Bill & Melinda Gates Foundation | — | investor | Grant agreement for cell line development of monoclonal antibodies targeting respiratory syncytial virus and malaria. | 2024-11-26 | View |
| Proliant Biologicals, LLC d/b/a Proliant Health and Biologicals | — | partner | License and Development Agreement for fungal microbial expression platforms and microbial strains | 2024-07-02 | View |
| Proliant Biologicals, LLC | — | partner | Licensee of Dyadic's proprietary fungal microbial expression and production platforms for recombinant serum albumin prod | 2024-07-02 | View |
| Rubic One Health | — | licensee | Signed an expanded licensing agreement with Dyadic to research, develop, manufacture, and distribute vaccines in African | 2023-04-12 | View |
| Alphazyme, LLC | — | target | Dyadic International, Inc. sold its equity interest in Alphazyme, LLC for approximately US$1.27 million. | 2023-01-23 | View |
| Janssen Biotech, Inc. | — | partner | Entered into a Research, License, and Collaboration Agreement for the manufacture of therapeutic protein candidates usin | 2021-12-17 | View |
| Johnson & Johnson | JNJ | partner | Parent company of Janssen Biotech, Inc., a party to the Research, License, and Collaboration Agreement. | 2021-12-17 | View |
| Sorrento Therapeutics, Inc. | — | licensee | Entered into an exclusive license agreement to utilize Dyadic's C1 technology for vaccine and therapeutic development. | 2021-08-11 | View |
| CR2O B.V. | — | supplier | Provider of pre-clinical and clinical trial services for Dyadic International's COVID-19 vaccine candidate. | 2021-06-03 | View |
| CR2O B.V. | — | supplier | Engaged to oversee and perform pre-clinical and clinical trial services for Dyadic's vaccine candidate. | 2021-03-18 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-25 | Delisting Notice | View | |
| 2026-08-14 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-08-12 | Earnings Release; Exhibits | View | |
| 2026-07-24 | Other Events; Exhibits | View | |
| 2026-06-22 | Shareholder Vote | View | |
| 2026-06-18 | Delisting Notice | View | |
| 2026-06-15 | Regulation FD; Exhibits | View | |
| 2026-05-28 | Regulation FD; Exhibits | View | |
| 2026-05-13 | Earnings Release; Exhibits | View | |
| 2026-03-30 | Delisting Notice | View | |
| 2026-03-25 | Earnings Release; Exhibits | View | |
| 2026-03-06 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-12-29 | Notice of Delisting or Transfer | View | |
| 2025-12-29 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-11-12 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-07 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-16 | Entry into Material Definitive Agreement; Financial Statements and Exhibits | Agreement | View |
| 2025-08-13 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-08-01 | Entry into Material Definitive Agreement; Other Events; Financial Statements and Exhibits | Agreement | View |
| 2025-07-23 | Regulation FD Disclosure; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR